The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > COMMENTARY
COMMENTARY
-
Pharmaceutical Partnerships in Japan for Regulatory and Commercial Success
June 30, 2008
-
COMMENTARY 4 articles
June 9, 2008
-
COMMENTARY/Shaking Pharmaceutical Administration System
May 19, 2008
-
COMMENTARY/Personnel Strategy -New Graduates or Work-Ready MRs?
April 21, 2008
-
COMMENTARY/Industry-Academia Cooperation Essential for Practical Use of iPS Cells
April 21, 2008
-
COMMENTARY/Improvement of Drug Distribution Business Practices Goes into Crucial Stretch
April 14, 2008
-
COMMENTARY/Mr Kodama Owes His Sweeping Victory to Members' Desire for Change: JPA
March 31, 2008
-
COMMENTARY/Most Mainstay Products Avoid Deep Price Cuts in FY2008 NHI Price Revision
March 31, 2008
-
Methodologic Issues in the Clinical Trial Study of Depression
March 24, 2008
-
COMMENTARY/Preparations for New OTC Drug Marketing System Enter Final Stage
March 3, 2008
-
COMMENTARY/Major Wholesalers vs Hansha Competition to Intensify on Growing Market for Generics
March 3, 2008
-
COMMENTARY/Japan Needs to Create Attractive "Stadium for Drug Discovery" and Invite Top-Level Players
February 25, 2008
-
COMMENTARY/Revision of Medical Fees May Increase Use of Drugs for Stroke, Mental Illnesses, Cancer
February 11, 2008
-
Current New Drug Development in the Japanese Pharmaceutical Industry(2)
February 11, 2008
-
Current New Drug Development in the Japanese Pharmaceutical Industry(1)
February 11, 2008
-
COMMENTARY/Generic Makers Increase Investment, but Will Consumption Really Increase as Gov't Hopes?
February 4, 2008
-
COMMENTARY/Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
-
OPINION/The East versus West Dilemma
January 28, 2008
-
COMMENTARY/Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
-
No More Need for MRs? -A Hell beyond the 2010 Crisis?-
January 14, 2008
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…